WhaleCreep

Avidity Partners Management LP 13F holdings, Q3 2025

Hedge fundSEC filingsCompare with another fundHoldings as of 2025-09-30, filed 2025-11-14

Avidity Partners Management LP disclosed 43 US equity positions worth $439.4m in its Q3 2025 13F filing. Its largest position is DNTH at 28.7% of the reported book, followed by CGON and MDT. Versus Q2 2025 it opened 13 new positions, added to 8, reduced 20 and exited 25.

$439m
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
43
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
28.7%
Largest position
The largest single position as a share of the reported equity book.
66.4%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
9
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
27
Quarters on file since Q4 2019
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q2 2025: 13 new, 8 added, 20 reduced, 25 exited

43 rows
DNTH DIANTHUS THERAPEUTICS INCHealthcare28.7%$126m3.20m+84%added
CGON CG ONCOLOGY INCHealthcare14.7%$64.5m1.60m+6.7%added
MDT Medtronic PlcHealthcare4.1%$18.2m190,600–new
BSX BOSTON SCIENTIFIC CORPHealthcare3.7%$16.0m164,300−49%reduced
ORKA ORUKA THERAPEUTICS INCHealthcare2.9%$12.7m660,424+88%added
BMY BRISTOL-MYERS SQUIBB COHealthcare2.6%$11.6m257,600–new
NTRA NATERA INCHealthcare2.6%$11.3m70,400−65%reduced
DHR DANAHER CORP DELHealthcare2.5%$10.8m54,700−39%reduced
TEVA TEVA PHARMACEUTICAL INDS LTDHealthcare2.3%$10.3m510,000−26%reduced
CATX PERSPECTIVE THERAPEUTICS INC–2.3%$10.3m2.99m+61%added
JBIO JADE BIOSCIENCES INCHealthcare2.2%$9.7m1.13m0.0%held
PFE PFIZER INCHealthcare2.1%$9.3m366,400–new
TMO THERMO FISHER SCIENTIFIC INCHealthcare2.1%$9.2m18,900−36%reduced
CNTX CONTEXT THERAPEUTICS INC–2.0%$8.7m8.98m+20%added
GMAB GENMAB A/SHealthcare1.7%$7.6m248,100−62%reduced
METSERA INC no ticker–1.7%$7.4m140,500–new
UNH UNITEDHEALTH GROUP INCHealthcare1.4%$6.1m17,800−44%reduced
ARVN ARVINAS INCHealthcare1.4%$6.0m698,363+187%added
COR CENCORA INCHealthcare1.4%$5.9m19,000−42%reduced
EHC ENCOMPASS HEALTH CORPHealthcare1.2%$5.3m41,900−43%reduced
JNJ JOHNSON & JOHNSONHealthcare1.1%$5.0m26,800–new
CI THE CIGNA GROUPHealthcare1.1%$4.8m16,600–new
ABBV ABBVIE INCHealthcare1.0%$4.6m19,800–new
MCK MCKESSON CORPHealthcare1.0%$4.5m5,800−57%reduced
CARL CARLSMED INC–1.0%$4.3m321,912–new
KVUE KENVUE INCConsumer Defensive1.0%$4.3m265,200–new
IMUX IMMUNIC INCHealthcare0.9%$4.1m4.70m−16%reduced
ARQT ARCUTIS BIOTHERAPEUTICS INCHealthcare0.9%$4.0m214,400−20%reduced
EXK EXACT SCIENCES CORPBasic Materials0.9%$4.0m73,600−79%reduced
PHAT PHATHOM PHARMACEUTICALS INCHealthcare0.8%$3.6m306,000−71%reduced
RGEN REPLIGEN CORPHealthcare0.7%$3.1m23,300−78%reduced
ACAD ACADIA PHARMACEUTICALS INCHealthcare0.7%$3.1m144,000–new
ASND ASCENDIS PHARMA A/SHealthcare0.7%$2.9m14,500–new
ELVN ENLIVEN THERAPEUTICS INCHealthcare0.7%$2.9m140,300+1142%added
BEAM BEAM THERAPEUTICS INCHealthcare0.6%$2.7m112,000−73%reduced
SCYX SCYNEXIS INC–0.6%$2.6m3.35m+173%added
HQY HEALTHEQUITY INCHealthcare0.5%$2.4m25,300−73%reduced
WVE WAVE LIFE SCIENCES LTDHealthcare0.5%$2.2m297,500–new
XENE XENON PHARMACEUTICALS INCHealthcare0.5%$2.1m53,400−51%reduced
AKROEUR AKERO THERAPEUTICS INC–0.4%$1.9m40,500−70%reduced
INSM INSMED INCHealthcare0.4%$1.7m11,600−80%reduced
KPTI KARYOPHARM THERAPEUTICS INC–0.2%$880k134,5660.0%held
IMRX IMMUNEERING CORP–0.1%$636k90,900–new

Exited since Q2 2025

25 rows
THC TENET HEALTHCARE CORP3.7%$18.7m
DXCM DEXCOM INC3.7%$18.4m
HNGE HINGE HEALTH INC3.3%$16.7m
ISRG INTUITIVE SURGICAL INC3.0%$14.7m
AXSM AXSOME THERAPEUTICS INC.2.0%$9.9m
RVMD REVOLUTION MEDICINES INC1.7%$8.4m
OMDA OMADA HEALTH INC1.4%$7.1m
HUM HUMANA INC1.4%$6.7m
OGN ORGANON & CO1.2%$6.2m
BBIO BRIDGEBIO PHARMA INC1.2%$6.0m
MDGL MADRIGAL PHARMACEUTICALS INC1.2%$5.8m
RARE ULTRAGENYX PHARMACEUTICAL IN1.1%$5.6m
DOCS DOXIMITY INC0.7%$3.7m
VRNA VERONA PHARMA PLC0.6%$3.2m
UNIQURE NV no ticker0.6%$2.9m
APGE APOGEE THERAPEUTICS INC0.6%$2.8m
SLNOEUR SOLENO THERAPEUTICS INC0.5%$2.7m
CAH CARDINAL HEALTH INC0.5%$2.5m
SPRY ARS PHARMACEUTICALS INC0.5%$2.4m
2KZ0 KEZAR LIFE SCIENCES INC0.5%$2.3m
NTLA INTELLIA THERAPEUTICS INC0.4%$2.2m
MLTX MOONLAKE IMMUNOTHERAPEUTICS0.4%$1.8m
SNDX SYNDAX PHARMACEUTICALS INC0.3%$1.4m
ALT ALTIMMUNE INC0.08%$406k
REVIVA PHARMACEUTCLS HLDGS I no ticker0.01%$52.6k

Sector mix

  • Healthcare89.8%
  • Unclassified8.3%
  • Consumer Defensive1.0%
  • Basic Materials0.9%

Book over time

Every quarter on file (27)
QuarterPositionsEquity book
Q2 202645$624m
Q1 202645$494m
Q4 202539$347m
Q3 202543$439m
Q2 202555$499m
Q1 202563$485m
Q4 202461$1.0bn
Q3 202481$2.0bn
Q2 202485$2.4bn
Q1 202487$2.8bn
Q4 202372$2.6bn
Q3 202383$2.5bn
Q2 202393$2.9bn
Q1 202383$3.0bn
Q4 202284$4.3bn
Q3 202296$4.6bn
Q2 202282$4.4bn
Q1 202291$4.5bn
Q4 202197$4.7bn
Q3 2021103$3.9bn
Q2 2021112$3.7bn
Q1 202193$3.6bn
Q4 202094$3.0bn
Q3 202066$1.9bn
Q2 202057$1.6bn
Q1 202049$698m
Q4 201933$159m

Where Avidity Partners Management LP was early

46 rows
BTAI BIOXCEL THERAPEUTICS INCQ1 20202 of 560.7%1.3%4Exited by Q1 2021+3.4%
ALEC ALECTOR INCQ1 20205 of 872.5%2.5%2Exited by Q3 2020+1.3%
VSTM VERASTEM INCQ1 20205 of 1001.1%1.1%2Exited by Q3 2020−35%
AXSM AXSOME THERAPEUTICS INCQ1 20208 of 1411.7%2.1%17Exited by Q3 2025+77%
IDYA IDEAYA BIOSCIENCES INCQ2 20201 of 1081.2%2.9%19Exited by Q2 2025+15%
ZNTL ZENTALIS PHARMACEUTICALS INCQ2 20203 of 872.1%4.8%14Exited by Q4 2023−58%
VIR VIR BIOTECHNOLOGY INCQ2 20204 of 1141.6%1.7%11Held at last filing, Q2 2026−75%
LEGN LEGEND BIOTECH CORPQ2 20205 of 1210.3%2.6%14Held at last filing, Q2 2026−32%
NTLA INTELLIA THERAPEUTICS INCQ2 20206 of 1290.6%1.7%16Held at last filing, Q2 2026−20%
SNDX SYNDAX PHARMACEUTICALS INCQ2 20206 of 1271.5%3.5%21Exited by Q3 2025−37%
ARVN ARVINAS INCQ2 20208 of 1212.3%5.1%22Exited by Q4 2025−75%
AVTR AVANTOR INCQ2 20209 of 1841.8%6.2%17Exited by Q2 2025−4.7%
NBP I MABQ3 20202 of 663.4%3.4%5Exited by Q4 2021+54%
NTRA NATERA INCQ3 202010 of 1672.0%6.8%23Exited by Q2 2026+177%
MRVI MARAVAI LIFESCIENCES HLDGS IQ4 20201 of 1163.2%3.3%3Exited by Q3 2021+49%
ATEC ALPHATEC HLDGS INCQ4 20203 of 1020.9%1.1%10Exited by Q4 2023−11%
ORGO ORGANOGENESIS HLDGS INCQ4 20203 of 671.4%1.4%2Exited by Q2 2021+142%
SHC SOTERA HEALTH COQ4 20203 of 1320.6%1.6%5Exited by Q1 2022−14%
STTK SHATTUCK LABS INCQ4 20203 of 651.7%1.7%5Exited by Q1 2022−84%
SGRY SURGERY PARTNERS INCQ4 20205 of 1320.5%3.8%11Exited by Q1 2025−27%
IMCR IMMUNOCORE HLDGS PLCQ1 20212 of 970.7%2.1%15Exited by Q4 2024−27%
NUVB NUVATION BIO INCQ1 20213 of 972.2%2.2%6Exited by Q3 2022−69%
ACET ADICET BIO INCQ1 20217 of 720.8%1.4%5Exited by Q2 2022+53%
CGEM CULLINAN THERAPEUTICS INCQ1 20219 of 920.8%1.2%3Exited by Q4 2024−60%
BBIO BRIDGEBIO PHARMA INCQ1 202113 of 1741.4%1.4%6Held at last filing, Q2 2026+21%
CMPS COMPASS PATHWAYS PLCQ2 20214 of 1071.0%1.0%2Exited by Q4 2021−22%
DOCS DOXIMITY INCQ2 20218 of 1330.2%1.5%3Exited by Q3 2025+5.4%
STVN STEVANATO GROUP S P AQ3 20212 of 621.6%1.6%2Exited by Q1 2022−11%
CRBU CARIBOU BIOSCIENCES INCQ3 20214 of 731.5%1.5%11Exited by Q2 2024−78%
ALT ALTIMMUNE INCQ3 20218 of 1040.6%1.5%10Exited by Q3 2025−66%
KYMR KYMERA THERAPEUTICS INCQ3 20219 of 980.8%2.0%4Exited by Q1 2025−32%
RARE ULTRAGENYX PHARMACEUTICAL INQ3 20219 of 1511.0%3.2%16Exited by Q3 2025−60%
RVMD REVOLUTION MEDICINES INCQ2 20228 of 1640.6%1.9%14Exited by Q2 2026+399%
PLRX PLIANT THERAPEUTICS INCQ3 202210 of 1030.9%2.4%4Exited by Q3 2023−13%
TMDX TRANSMEDICS GROUP INCQ3 202210 of 1080.3%1.2%3Exited by Q1 2025+49%
PCVX VAXCYTE INCQ3 202213 of 1210.3%1.8%9Exited by Q2 2025+57%
BHVN BIOHAVEN LTDQ4 20229 of 1260.5%1.9%10Exited by Q2 2025+73%
ICLR ICON PLCQ4 202215 of 1611.0%1.7%4Exited by Q2 2026−43%
GPCR STRUCTURE THERAPEUTICS INCQ2 20239 of 1140.06%1.8%8Held at last filing, Q2 2026+29%
MLTX MOONLAKE IMMUNOTHERAPEUTICSQ2 202311 of 1210.7%1.8%4Exited by Q2 2026−63%
NMRA NEUMORA THERAPEUTICS INC.Q3 20233 of 751.0%1.3%5Exited by Q4 2024−6.4%
DNTH DIANTHUS THERAPEUTICS INCQ3 20235 of 970.7%35.8%12Held at last filing, Q2 2026+613%
CGON CG ONCOLOGY INCQ1 20242 of 882.3%17.7%10Held at last filing, Q2 2026+62%
JANX JANUX THERAPEUTICS INCQ1 20249 of 1090.5%4.0%5Exited by Q2 2025−28%
ORKA ORUKA THERAPEUTICS INCQ3 20247 of 831.0%11.6%8Held at last filing, Q2 2026+288%
JBIO JADE BIOSCIENCES INCQ2 20252 of 522.3%6.2%5Held at last filing, Q2 2026+122%

Concentration and tenure

6.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
39.7%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
2
Median completed holding, quarters